The stubborn persistence of adult pneumococcal pneumonia as a public health problem

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 5, 2014, Pages 1319-1321

  Hollingsworth, Rosalind ^a   Isturiz, Raul ^a  

^a PFIZER INC   (United States)

Author keywords

Adults; Bacterial; Clinical; Conjugate; Pneumococcal; Polysaccharide vaccine; Protein conjugate vaccine; Vaccination; Vaccinology

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; INFECTION PREVENTION; LETTER; MEDICAL RECORD; NETHERLANDS; PERSISTENT INFECTION; PUBLIC HEALTH PROBLEM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTYPING; STREPTOCOCCUS PNEUMONIA; UNITED KINGDOM; UNITED STATES; VACCINATION; IMMUNOLOGY; PROCEDURES;

HUMANS; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 84901437379     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27986     Document Type: Letter

References (32)

1. Fedson DS. Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al. Hum Vaccin Immunother 2013; 10; (Forthcoming); PMID:24030320
2. Hollingsworth R, Isturiz R. Pneumococcal vaccination of older adults: Conjugate or polysaccharide? Hum Vaccin Immunother 2013; 10:10; (Forthcoming); PMID:24018552
3. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422; PMID:23440780
4. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58; PMID:19124790; http://dx.doi.org/10.1503/cmaj.080734
5. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802-8; PMID:23000122; http://dx.doi.org/10.1016/j.vaccine.2012.09.019
6. Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31:3585-93; PMID:23688527; http://dx.doi.org/10.1016/j.vaccine. 2013.05.010
7. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
8. Prevnar 13®. Full Prescribing Information, Pfizer, Inc., Collegevill, PA, USA, 2011.
9. FDA Briefing Document for Prevnar 13™ (PCV13):Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein). 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ BloodVaccinesandOtherBiologics/ VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM279681.pdf
10. European Medicines Agency. Prevenar 13 (pneumococcal polysaccharide conjugate vaccine): Assessment report. 2011.
11. Ortqvist A, Henckaerts I, Hedlund J, Poolman J. Non-response to specific serotypes likely cause for failure to 23-valent pneumococcal polysaccharide vaccine in the elderly. Vaccine 2007; 25:2445-50; PMID:17052816; http://dx.doi.org/10.1016/j.vaccine.2006.09.018
12. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012; 30:5437-44; PMID:22728289; http://dx.doi.org/10.1016/j.vaccine.2012.05.076
13. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804-12; PMID:22357831; http://dx.doi.org/10.1001/jama.2012.169
14. Smith KJ. Determining the cost-effectiveness of adult pneumococcal vaccination strategies. Expert Rev Pharmacoecon Outcomes Res 2013
15. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011; 2:e00309-10; PMID:21264063; http://dx.doi.org/10.1128/mBio.00309-10
16. Nelson JC, Jackson M, Yu O, Whitney CG, Bounds L, Bittner R, Zavitkovsky A, Jackson LA. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008; 26:4947-54; PMID:18662735; http://dx.doi.org/10.1016/j.vaccine.2008.07.016
17. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369:1179-86; PMID:17416262; http://dx.doi.org/10.1016/S0140-6736(07)60564-9
18. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CGUS. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63; PMID:23841730; http://dx.doi.org/10.1056/ NEJMoa1209165
19. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
20. Kim L, Gierke R, Lewis E, Link-Gelles R, Farley M, Schaffner W, Thomas A, Reingold A, Harrison L, Lynfield R, et al. Indirect Effects of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Pneumonia in Adults Presented at: IDWeek; October 4-6, 2013, 2013; San Francisco, CA.
21. Cortellaro F, Colombo S, Coen D, Duca PG. Lung ultrasound is an accurate diagnostic tool for the diagnosis of pneumonia in the emergency department. Emerg Med J 2012; 29:19-23; PMID:21030550; http://dx.doi.org/10.1136/emj.2010. 101584
22. Hayden GE, Wrenn KW. Chest radiograph vs. computed tomography scan in the evaluation for pneumonia. J Emerg Med 2009; 36:266-70; PMID:18571356; http://dx.doi.org/10.1016/j.jemermed.2007.11.042
23. Self WH, Courtney DM, McNaughton CD, Wunderink RG, Kline JA. High discordance of chest x-ray and computed tomography for detection of pulmonary opacities in ED patients: implications for diagnosing pneumonia. Am J Emerg Med 2013; 31:401-5; PMID:23083885; http://dx.doi.org/10.1016/j.ajem.2012.08.041
24. Esayag Y, Nikitin I, Bar-Ziv J, Cytter R, Hadas-Halpern I, Zalut T, Yinnon AM. Diagnostic value of chest radiographs in bedridden patients suspected of having pneumonia. Am J Med 2010; 123:e1-5; PMID:20102999; http://dx.doi.org/10.1016/j.amjmed.2009.09.012
25. Syrjälä H, Broas M, Suramo I, Ojala A, Lähde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998; 27:358-63; PMID:9709887; http://dx.doi.org/10. 1086/514675
26. Bourcier JE, Paquet J, Seinger M, Gallard E, Redonnet JP, Cheddadi F, Garnier D, Bourgeois JM, Geeraerts T. Performance comparison of lung ultrasound and chest x-ray for the diagnosis of pneumonia in the ED. Am J Emerg Med 2014; 32:115-8; PMID:24184011; http://dx.doi.org/10.1016/j.ajem.2013.10.003
27. Grijalva CG, Griffin MR. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Rev Vaccines 2008; 7:83-95; PMID:18251696; http://dx.doi.org/10.1586/14760584.7.1.83
28. Sherwin RL, Gray S, Alexander R, McGovern P, Graepel J, Pride MW, Purdy J, File TM. Distribution of PCV13-serotype Streptococcus pneumoniae in adults aged ≥ 50 years presenting to select US hospitals with radiographically- confirmed community-onset pneumonia [abstract 511]. Presented at: ID Week; October 17-21, 2012; San Diego, CA.
29. Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-83; PMID:18990781
30. Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines 2010; 9:229-36; PMID:20218848; http://dx.doi.org/10. 1586/erv.10.6
31. Bewick T, Sheppard C, Greenwood S, Slack M, Trotter C, George R, Lim WS. Serotype prevalence in adults hospitalised with pneumococcal noninvasive community-acquired pneumonia. Thorax 2012; 67:540-5; PMID:22374921; http://dx.doi.org/10.1136/thoraxjnl-2011-201092
32. Van der Linden M, Perniciaro SR, Imohl M. Pneumococcal Conjugate Vaccines In German Children And Adults Presented at: ICAAC; Sept 10-13, 2013, 2013; Denver, CO, USA.